Switch theme
Sign up to access all valuation multiples
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
1983
140
LTM Revenue $1.2M
LTM EBITDA -$88.0M
-$71.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Perspective Therapeutics has a last 12-month revenue of $1.2M and a last 12-month EBITDA of -$88.0M.
In the most recent fiscal year, Perspective Therapeutics achieved revenue of n/a and an EBITDA of -$78.1M.
Perspective Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Perspective Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | $0.8M | n/a | XXX | XXX | XXX |
| Gross Margin | Infinity% | NaN% | XXX | XXX | XXX |
| EBITDA | -$39.1M | -$78.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$7.3M | -$46.5M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Perspective Therapeutics's stock price is $2.
Perspective Therapeutics has current market cap of $152M, and EV of -$71.0M.
See Perspective Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$71.0M | $152M | XXX | XXX | XXX | XXX | $-1.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Perspective Therapeutics has market cap of $152M and EV of -$71.0M.
Perspective Therapeutics's trades at -57.5x LTM EV/Revenue multiple, and 0.8x LTM EBITDA.
Analysts estimate Perspective Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Perspective Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$71.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | XXX | XXX |
| P/E | -1.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPerspective Therapeutics's NTM/LTM revenue growth is -43%
Perspective Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Perspective Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Perspective Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Perspective Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 100% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| Senseonics Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Perspective Therapeutics acquired XXX companies to date.
Last acquisition by Perspective Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Perspective Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Perspective Therapeutics founded? | Perspective Therapeutics was founded in 1983. |
| Where is Perspective Therapeutics headquartered? | Perspective Therapeutics is headquartered in United States of America. |
| How many employees does Perspective Therapeutics have? | As of today, Perspective Therapeutics has 140 employees. |
| Who is the CEO of Perspective Therapeutics? | Perspective Therapeutics's CEO is Mr. Johan M. Spoor. |
| Is Perspective Therapeutics publicy listed? | Yes, Perspective Therapeutics is a public company listed on ASE. |
| What is the stock symbol of Perspective Therapeutics? | Perspective Therapeutics trades under CATX ticker. |
| When did Perspective Therapeutics go public? | Perspective Therapeutics went public in 2005. |
| Who are competitors of Perspective Therapeutics? | Similar companies to Perspective Therapeutics include e.g. Philips, SmartVest, InfuSystem, Myomo. |
| What is the current market cap of Perspective Therapeutics? | Perspective Therapeutics's current market cap is $152M |
| What is the current revenue of Perspective Therapeutics? | Perspective Therapeutics's last 12-month revenue is $1.2M. |
| What is the current EBITDA of Perspective Therapeutics? | Perspective Therapeutics's last 12-month EBITDA is -$88.0M. |
| What is the current EV/Revenue multiple of Perspective Therapeutics? | Current revenue multiple of Perspective Therapeutics is -57.5x. |
| What is the current EV/EBITDA multiple of Perspective Therapeutics? | Current EBITDA multiple of Perspective Therapeutics is 0.8x. |
| Is Perspective Therapeutics profitable? | Yes, Perspective Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
